Company intelligence / Profile preview

Innoviva, Inc.

Burlingame, California, United Statesinva.com ↗

Ownership: Public · INVA
Development stage: Commercial

Overview

Innoviva is a diversified holding company with a portfolio of royalties from respiratory assets partnered with GSK, as well as commercial products in critical care and infectious diseases through its Innoviva Specialty Therapeutics division. The company has strategically diversified beyond royalty management through key acquisitions, transforming its focus.

Therapeutic areas: OtherPulmonologyInfectious Diseases
Modalities: Small molecules
Industry: Biotech

Drug pipeline

16 assets

Angiotensin II

Approved

15 more assets in the full pipeline.

Request access →

Partnerships

GlaxoSmithKline (GSK)Armata

Financials

Market cap: $1.6B
Total revenue: $98M
Enterprise value: $1.3B

Beyond the preview

Go deeper on Innoviva, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Innoviva, Inc..

Explore the full profile